ArticleOncoimmunology
Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Identification of bronchial epithelial genes associated with type 2 eosinophilic inflammation in asthma.The Journal of allergy and clinical immunology · 2025Article
- Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma.Apoptosis : an international journal on programmed cell death · 2025Article
- Cell-in-cell associated lncRNA signature predicts prognosis and immunotherapy response in gastric cancer.Frontiers in oncology · 2025Article
- Targeting tumor-associated macrophages in gastric cancer progression and therapy: insights from molecular mechanisms to therapeutic applications.Frontiers in pharmacology · 2025Review
- Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- DOKing tumor progression in ccRCC.Journal of Cancer · 2024Article
- Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy.International journal of molecular sciences · 2023Review
- Tumour-associated macrophages in gastric cancer: From function and mechanism to application.Clinical and translational medicine · 2023Review
- Peroxisome proliferator-activated receptors regulate the progression and treatment of gastrointestinal cancers.Frontiers in pharmacology · 2023Review
- Comprehensive analysis of DOK family genes expression, immune characteristics, and drug sensitivity in human tumors.Journal of advanced research · 2022Article
- Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer.Frontiers in immunology · 2022Review
- How Macrophages Become Transcriptionally Dysregulated: A Hidden Impact of Antitumor Therapy.International journal of molecular sciences · 2021Review
- PPAR-γ Modulators as Current and Potential Cancer Treatments.Frontiers in oncology · 2021Review
- Mining TCGA database for genes of prognostic value in gastric cancer microenvironment.Journal of cellular and molecular medicine · 2020Article
- Structure, Function, and Regulation of the SRMS Tyrosine Kinase.International journal of molecular sciences · 2020Review
- Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Transition in Gastric Carcinogenesis.International journal of molecular sciences · 2020Review
- The Emerging Role of GC-MSCs in the Gastric Cancer Microenvironment: From Tumor to Tumor Immunity.Stem cells international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Docking protein-1 (DOK1) is a tumor suppressor frequently lost in malignant cells, however, it retains the ability to control activities of immune receptors in adjacent stroma cells of the tumor microenvironment. We therefore hypothesized that addressing DOK1 may be useful for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.